All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study-Reference-Cited by-同舟云学术

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Published:2014-11 Issue:9954 Volume:384 Page:1597-1605
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Manns Michael,Pol Stanislas,Jacobson Ira M,Marcellin Patrick,Gordon Stuart C,Peng Cheng-Yuan,Chang Ting-Tsung,Everson Gregory T,Heo Jeong,Gerken Guido,Yoffe Boris,Towner William J,Bourliere Marc,Metivier Sophie,Chu Chi-Jen,Sievert William,Bronowicki Jean-Pierre,Thabut Dominique,Lee Youn-Jae,Kao Jia-Horng,McPhee Fiona,Kopit Justin,Mendez Patricia,Linaberry Misti,Hughes Eric,Noviello Stephanie

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population;Manos;J Med Virol,2012

2. Diagnosis, management, and treatment of hepatitis C: an update;Ghany;Hepatology,2009

3. EASL Clinical Practice Guidelines: management of hepatitis C virus infection;J Hepatol,2014

4. The global health burden of hepatitis C virus infection;Negro;Liver Int,2011

5. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel;Cornberg;Liver Int,2011

Cited by 307 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030.;Journal of Infection and Public Health;2024-07

2. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals;Expert Opinion on Pharmacotherapy;2024-05-02

3. Efficacy of combined antiretroviral therapy (cART) in Hepatitis B and C associated hepatocellular carcinoma (HCC): a narrative review;Journal of Human Virology & Retrovirology;2023-12-29

4. Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells;Molecular Cancer Therapeutics;2023-01-11

5. Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice;Viruses;2022-06-17